TELA Bio, which sells soft tissue implants used in hernia repair and reconstructive surgery, raised $52 million by offering 4 million shares at $13, below the range of $14 to $16, to command a fully diluted market value of $142 million. TELA Bio plans to list on the Nasdaq under the symbol TELA. Jefferies and Piper Jaffray acted as lead managers on the deal.
Investment Disclosure: Renaissance IPO ETF (symbol: IPO) Renaissance International ETF (symbol: IPOS)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.